Peptide Stacks for Cellular Regeneration: What the CJC-1295, Ipamorelin, and BPC-157 Combinations Actually Do

You've been lifting seriously for six years, sleeping eight hours, doing everything the biohacking content tells you to do — and then a blood panel at 41 comes back showing IGF-1 at 98 ng/mL, well below the 115–300 ng/mL reference range for your age group. Recovery is slower than it was at 35, body composition has drifted despite no changes in diet, and your joints feel older than your training log suggests they should. Something has changed at the cellular level. The question is whether targeted peptide protocols can actually move those numbers — and which combinations justify the cost.

What "Stacking" Actually Means in This Context

Peptide stacking isn't a marketing concept. It's a pharmacological logic: combine compounds with different mechanisms but complementary endpoints, so they address the same physiological goal through parallel pathways rather than redundant ones. For cellular regeneration and longevity specifically, that usually means pairing a growth hormone secretagogue — something that drives IGF-1 and GH pulse amplitude — with a tissue-repair peptide that operates through local, receptor-mediated healing rather than the systemic GH axis.

The most commonly documented stack in this space combines CJC-1295 with Ipamorelin. CJC-1295 (without DAC) works as a GHRH analogue with a half-life of roughly 30 minutes, while Ipamorelin is a ghrelin mimetic that stimulates pulsatile GH release without the cortisol or prolactin side effects associated with older secretagogues like GHRP-6. In a 2006 study by Teichman et al. published in the Journal of Clinical Endocrinology & Metabolism, CJC-1295 with DAC increased mean GH concentrations by 2- to 10-fold and IGF-1 by 1.3- to 1.7-fold across doses from 30 to 120 mcg/kg. Those are real signal magnitudes on real biomarkers — not proxy endpoints.

The Repair Layer: BPC-157 and Its Role in the Stack

The second tier of a regeneration-focused stack typically involves BPC-157, a 15-amino-acid peptide derived from a protective gastric protein. Its mechanism differs fundamentally from the GH secretagogue axis — it operates largely through nitric oxide signalling and VEGF-mediated angiogenesis, promoting tendon, ligament, gut lining, and neural tissue repair at the local level.

Clinically documented dosing in animal studies has ranged from 1 to 10 mcg/kg, placing a 70 kg human equivalent somewhere in the 200–500 mcg/day range depending on the indication. For gut and systemic repair, oral BPC-157 is sometimes used; for musculoskeletal tissue, subcutaneous injection closer to the affected site produces more targeted results. BPC-157 is not a GH-axis compound — adding it to a CJC/Ipamorelin protocol doesn't create redundancy, it creates a different repair signal running in parallel.

BPC-157 remains a research compound in the US and a grey-area peptide in the UK, so access and sourcing vary by geography. Anyone in the UK researching this specifically can find regulated clinical options through BPC-157 clinics in the UK.

When to Add a GHRH Base: Sermorelin's Place in Longer Protocols

For protocols running longer than three months, some clinicians use sermorelin rather than CJC-1295 as the GHRH-analogue base. Sermorelin has the longest clinical track record of the secretagogue class — it was FDA-approved under the brand name Geref as a diagnostic agent in 1990 and used therapeutically in paediatric GH deficiency through the late 1990s. Its shorter half-life (around 10–20 minutes) means it more closely mimics physiological GHRH pulsatility, which some physicians argue is more appropriate for multi-year use in adults who are GH-insufficient rather than GH-deficient.

The tradeoff is potency. Sermorelin produces a more modest IGF-1 response than CJC-1295 with DAC. For a 45-year-old presenting with IGF-1 in the 90s ng/mL, a CJC/Ipamorelin combination is more likely to move the number meaningfully within a 12-week cycle; sermorelin is more appropriate as a maintenance protocol once levels have stabilised in the lower half of the reference range.

Dosing Protocols and Timing Logic

Timing matters more with secretagogues than most patients expect. GH is released in pulses — primarily during the first slow-wave sleep cycle and during fasting states. Injecting a GHRH analogue and a GHRP simultaneously 30–60 minutes before sleep amplifies the natural peak rather than creating an out-of-phase artificial one. Consuming carbohydrates within 90 minutes before injection significantly blunts the response through somatostatin suppression.

A common starting protocol for CJC-1295/Ipamorelin is 100 mcg of each, injected subcutaneously five nights per week, with two nights off to preserve receptor sensitivity. BPC-157, when layered in for connective tissue or gut repair, is typically run as a separate morning injection at 250 mcg daily for 8–12 week cycles. These figures reflect the receptor saturation kinetics and tolerance data available from existing animal and small human studies — they are not arbitrary.

Finding the Right Platform for a Structured Protocol

The logistics of running a legitimate, physician-supervised stack have improved substantially by 2026. Compounding pharmacy access, telehealth prescribing, and structured programs that include baseline labs, follow-up panels, and dose titration are now widely available in the US market. System Labs and Yucca Health both offer structured peptide programs with lab monitoring included — the kind of setup where you can track IGF-1 before and after rather than guessing whether the protocol is working. Costs in 2026 typically run $150–$400/month depending on the compounds included and whether labs are bundled.

For anyone not based in the US, the peptide clinics directory covers international options with filtering by location and treatment type.

The Honest Takeaway

The most common mistake with peptide stacks for longevity is treating them as supplements — running them without baseline labs, without a defined endpoint, and without a way to measure whether anything changed. The biology is real. The mechanism literature is solid enough to justify serious interest. A CJC/Ipamorelin/BPC-157 stack costs at least $200/month for a minimally adequate protocol, and the only way to know if it's working is to test IGF-1, recovery markers, and sleep quality at 8-week intervals and adjust accordingly. Stacking without tracking is expensive optimism.

---

Peptide Clinic Finder is a comparison platform. The author may receive compensation if you sign up through links on our partner pages.

---